Pharmaceutical

An American subsidiary of pharmaceutical major Cipla has initiated a voluntary recall of certain batches of its generic anti-cancer medication in the United States after manufacturing specifications were not met. The recall, classified as a Class III action by U.S. health regulators, affects more than 400 cartons of Nilotinib capsules available in two dosage strengths. The decision was taken as a precautionary measure following the identification of quality inconsistencies during manufacturing checks.

Glenmark Pharmaceuticals has introduced a generic version of Sodium Phosphates Injection in the United States, strengthening its foothold in the regulated injectable segment. The product, launched following approval from the US Food and Drug Administration, targets hospital and institutional markets where demand for cost-effective alternatives remains strong. The move reflects Glenmark’s strategy to deepen its presence in high-value, complex generics while diversifying revenue streams beyond oral solids. As pricing pressures persist across the U.S.

Zydus Lifesciences has received approval from the US Food and Drug Administration to market additional generic formulations in the United States, reinforcing its strategic focus on regulated markets. The authorization enables the company to expand its portfolio in high-value therapeutic segments and enhance revenue visibility from exports. Regulatory clearance from the USFDA is widely regarded as a quality benchmark in the global pharmaceutical industry.

Indian drugmaker Alembic Pharmaceuticals has received final approval from the U.S. Food and Drug Administration to market Lamotrigine orally disintegrating tablets in the United States. The authorization covers multiple strengths under the abbreviated new drug application pathway, confirming therapeutic equivalence to the reference listed drug, Lamictal, marketed by GlaxoSmithKline LLC. 

Indian pharmaceutical major Lupin Limited has received approval from the U.S. Food and Drug Administration for its generic version of a widely prescribed anti-seizure medication, reinforcing its strategic focus on complex generics in the United States. The regulatory clearance enables the company to market the product in the world’s largest pharmaceutical market, where demand for cost-effective neurological therapies remains robust. The approval is expected to bolster Lupin’s U.S. revenues and enhance its competitive positioning.

Pharmaceutical major Lupin Ltd. is facing regulatory scrutiny after officials from the Maharashtra Goods and Services Tax Department conducted a search operation at one of its offices. The action, linked to potential discrepancies in tax filings and input tax credit claims, signals heightened enforcement across India’s corporate landscape. While the company has stated it is cooperating fully with authorities, the development underscores increasing compliance expectations for large enterprises.

Pharmaceutical giant Zydus Lifesciences has launched a new biosimilar therapy targeting visual impairment, marking a significant advancement in ophthalmic care. The product offers an alternative to existing biologics, promising comparable efficacy at a more accessible cost, potentially reducing treatment expenditures for patients. Analysts view this launch as a strategic move to strengthen Zydus’s presence in the high-growth ophthalmology segment, which is witnessing rising demand due to aging populations and chronic eye conditions.

Lupin Limited is set to commercialize a newly approved antidepressant in Canada, marking a strategic expansion of its North American portfolio. The move strengthens the company’s specialty and central nervous system, or CNS, product pipeline in a market characterized by rising demand for mental health treatments. By leveraging its established regulatory and distribution infrastructure, Lupin aims to enhance revenue diversification and reinforce its global generics and branded formulations presence.

Piramal Pharma has received a Form 483 from the United States Food and Drug Administration following an inspection of one of its manufacturing facilities. The regulatory document outlines specific observations related to procedural or compliance gaps that require corrective action. While a Form 483 does not constitute a final regulatory action or import restriction, it signals areas where the company must strengthen quality systems and documentation practices. Piramal Pharma stated it will respond within the stipulated timeline and implement necessary remediation measures.

Cipla Ltd. disclosed that the U.S. Food and Drug Administration has issued a Form 483 with two observations following a Pre-Approval Inspection of its wholly owned subsidiary, InvaGen Pharmaceuticals, Inc. The inspection, conducted from Feb. 2 to Feb. 9, 2026, reviewed manufacturing operations at the U.S.-based facility. While a Form 483 does not constitute final regulatory action, it highlights areas where the agency believes improvements are warranted.